GlassScriptPhysician profile
Rachel L Rager
NPI 1841505377
$6,030.59
in general payments reported to CMS, 2019-2025
25 companies · $1,694 in 2025
The $1,694 reported for 2025 was more than what 93% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,017 · 2022: $883 · 2023: $1,196 · 2024: $1,239 · 2025: $1,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,130.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $810.96 | 2021-2025 | |
| Genzyme Corporation | $769.59 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $674.23 | 2021-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $482.54 | 2021-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $421.15 | 2021-2025 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $398.20 | 2024 | |
| Madrigal Pharmaceuticals | $343.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $325.22 | 2022-2024 | Linzess |
| Gilead Sciences, INC. | $308.53 | 2022-2025 | |
| Janssen Biotech, INC. | $304.74 | 2021-2025 | Stelara, Tremfya, Simponi |
| Regeneron Healthcare Solutions, INC. | $241.49 | 2022-2025 | Dupixent |
| Celgene Corporation | $185.69 | 2021-2023 | Zeposia |
| Lilly USA, LLC | $141.55 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $124.49 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $90.69 | 2021-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $89.68 | 2021-2023 | Avsola, Amjevita |
| Ipsen Biopharmaceuticals, INC | $66.04 | 2025 | Iqirvo |
| Pfizer INC. | $64.11 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $48.60 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $32.71 | 2025 | Rebyota |
| Organon LLC | $29.93 | 2023 | |
| Novo Nordisk INC | $27.47 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $20.94 | 2023 | Dificid |
| Celltrion USA INC. | $15.40 | 2025 | Vegzelma |
| Baxter Healthcare | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Rager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.